no worries. let Synergy play out over the next year...IBS-C data (although CIC is the FAR larger market), SP333 data and progression through trials, partnership, buyout or commercial plans.
Plecanatide will be approved, it already passed FDA primary endpoints.
The 72mcg dose for Linzess already showed less efficacy in the Phase 2 dose ranging study than the 145mcg dose...even it passes endpoints with less efficacy Plecanatide has a great marketing position against it.
Linzess and Plecanatide will both be competing in an EXPANDING GI market.